<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099031</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-INNOHEP-1093</org_study_id>
    <nct_id>NCT03099031</nct_id>
  </id_info>
  <brief_title>Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)</brief_title>
  <acronym>PREDICARE</acronym>
  <official_title>Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the Ottawa score (risk of thromboembolic
      recurrences) in cancer patients with thromboembolic disease treated with tinzaparin
      (Innohep®)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Ottawa score is a clinical predictive score aiming at stratifying thromboembolic
      recurrences in cancer patients according to identified clinical risk factors and histological
      type of the tumor. This score has never been validated externally in a prospective way in
      patients treated with tinzaparin. The objective of this observational prospective study is to
      enroll cancer patients with TED treated with tinzaparin for a planned period of 6 months and
      to collect data on thromboembolic recurrences, major hemorrhages, deaths and heparin-induced
      thrombocytopenia
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism recurrence</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heparin induced thrombocytopenia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Premature treatment discontinuation</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">420</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Tinzaparin</arm_group_label>
    <description>Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <description>Subcutaneous injection of 175 IU/kg once daily for 6 months</description>
    <arm_group_label>Tinzaparin</arm_group_label>
    <other_name>Innohep®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population from French general hospitals, anticancer centres, and university
        hospitals treating more than 1000 cancer patients per year
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer patients with histologically confirmed, active or evolving, solid or liquid
             tumour, or

          -  Suspected malignant tumour confirmed within a month of index VTE occurrence

          -  Treated with specific metastatic or adjuvant anti-cancer treatment

          -  Patients with recent diagnosis of documented symptomatic or incidental VTE and a
             prescription of tinzaparin for 6 months

          -  Proximal or distal VTE of lower limbs

          -  Pulmonary embolism

          -  Inferior or superior vena cava thrombosis

          -  Iliac vein thrombosis

        Exclusion Criteria:

          -  Skin cancer other than melanoma

          -  Life expectancy less than 6 months

          -  Superficial isolated thrombosis

          -  Isolated subsegmental pulmonary embolism

          -  Cerebral, visceral thrombosis

          -  Superior limbs VTE or Central catheter thrombosis

          -  Patients being treated with anticoagulants by more than 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G Meyer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de pneumologie et de soins intensifs, Hôpital Européen Georges Pompidou, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Scotte, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité fonctionnelle de soins oncologiques de support, Hôpital Européen Georges Pompidou, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ottawa score</keyword>
  <keyword>tinzaparin</keyword>
  <keyword>low-molecular weight heparin</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>venous thrombosis</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>hemostatic disorders</keyword>
  <keyword>vascular disease</keyword>
  <keyword>neoplasms</keyword>
  <keyword>breast neoplasms</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>prostatic neoplasms</keyword>
  <keyword>colorectal neoplasms</keyword>
  <keyword>genital neoplasms</keyword>
  <keyword>urogenital neoplasms</keyword>
  <keyword>intestinal neoplasms</keyword>
  <keyword>digestive system neoplasms</keyword>
  <keyword>lymphoma</keyword>
  <keyword>leukemia</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>lymphoproliferative disorders</keyword>
  <keyword>myeloproliferative disorders</keyword>
  <keyword>lymphatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

